Table 3.
Multivariate analysis of variables associated with HPD.
| Model-1 | Model-2 (MDA-ICI Score) | Model-3 (RMH Score) | ||||
|---|---|---|---|---|---|---|
| Variable | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p |
| Age (y) | ||||||
| <65 | Reference | 0.168 | Reference | 0.114 | ||
| ≥65 | 0.315 (0.061–1.631) | 0.259 (0.048–1.383) | ||||
| ECOG performance status | ||||||
| 0–1 | Reference | 0.056 | Reference | 0.023 | ||
| 2–4 | 3.761 (0.966–14.640) | 4.523 (1.227–16.676) | ||||
| Number of metastatic sites | ||||||
| <3 | Reference | 0.120 | Reference | 0.035 | ||
| ≥3 | 3.007 (0.750–12.059) | 3.546 (1.093–11.507) | ||||
| Liver metastasis | ||||||
| No | Reference | 0.894 | Reference | 0.555 | ||
| Yes | 1.093 (0.298–4.012) | 1.426 (0.439–4.633) | ||||
| LDH | ||||||
| Normal | Reference | |||||
| >ULN | 1.677 (0.433–6.497) | 0.455 | ||||
| ≥1.5 ULN | 2.522 (0.602–10.556) | 0.205 | ||||
| AEC/μL | ||||||
| <100 | 2.332 (0.713–7.626) | 0.161 | 2.960 (1.029–8.511) | 0.044 | 2.461 (0.814–7.446) | 0.111 |
| ≥100 | Reference | Reference | Reference | |||
| RMH score | ||||||
| Low risk | Reference | 0.026 | ||||
| High risk | 3.675 (1.166–11.580) | |||||
| MDA-ICI score | ||||||
| Low risk | Reference | |||||
| İntermediate risk | 2.375 (0.736–7.670) | 0.148 | ||||
| High risk | 4.466 (0.947–21.061) | 0.059 | ||||
Hazard ratios (HR) are presented with 95% confidence intervals (CI). Variables included in the multivariate analysis were selected based on their significance in the univariate analysis. Abbreviations: ECOG = Eastern Cooperative Oncology Group; LDH = Lactate Dehydrogenase; AEC = Absolute Eosinophil Count; ULN = Upper Limit of Normal; ICI = Immune Checkpoint Inhibitor; MDA-ICI = MD Anderson Immune Checkpoint Inhibitor Score; RMH = Royal Marsden Hospital Score. A p-value of <0.05 was considered statistically significant.